A Humar

Summary

Affiliation: University of Alberta
Country: Canada

Publications

  1. ncbi request reprint Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study
    Shahid Husain
    University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
    Transplantation 75:2023-9. 2003
  2. ncbi request reprint Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients
    Atul Humar
    University of Toronto, Toronto, Ontario, Canada
    Am J Transplant 5:1065-70. 2005
  3. ncbi request reprint An assessment of interactions between hepatitis C virus and herpesvirus reactivation in liver transplant recipients using molecular surveillance
    Atul Humar
    Department of Medicine, University of Alberta, Edmonton, AB, Canada
    Liver Transpl 13:1422-7. 2007
  4. pmc Quinolone prophylaxis for the prevention of BK virus infection in kidney transplantation: study protocol for a randomized controlled trial
    Atul Humar
    Department of Medicine, Faculty of Medicine and Dentistry, 2J2 00 WC Mackenzie Health Sciences Centre, University of Alberta, Edmonton, AB T6G 2R7, Canada
    Trials 14:185. 2013
  5. pmc Differential decay kinetics of human cytomegalovirus glycoprotein B genotypes following antiviral chemotherapy
    Vincent C Emery
    Centre for Virology, Department of Infection, University College Medical School, London, United Kingdom
    J Clin Virol 54:56-60. 2012
  6. doi request reprint An assessment of herpesvirus co-infections in patients with CMV disease: correlation with clinical and virologic outcomes
    A Humar
    Department of Medicine, University of Alberta, Edmonton, AB, Canada
    Am J Transplant 9:374-81. 2009
  7. doi request reprint Nucleic acid testing (NAT) of organ donors: is the 'best' test the right test? A consensus conference report
    A Humar
    Transplant Infectious Diseases, University of Alberta
    Am J Transplant 10:889-99. 2010
  8. doi request reprint The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients
    A Humar
    Department of Medicine, University of Alberta, Edmonton, AB, Canada
    Am J Transplant 10:1228-37. 2010
  9. ncbi request reprint Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study
    Atul Humar
    Transplant Infectious Diseases, University of Alberta, Edmonton, AB, Canada
    Transplantation 90:1427-31. 2010
  10. doi request reprint Analysis and clinical correlation of genetic variation in cytomegalovirus
    L F Lisboa
    Transplant Infectious Diseases, University of Alberta, Edmonton, Alberta, Canada
    Transpl Infect Dis 14:132-40. 2012

Detail Information

Publications62

  1. ncbi request reprint Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study
    Shahid Husain
    University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
    Transplantation 75:2023-9. 2003
    ..This study determines whether the spectrum, risk factors, and outcome of invasive candidiasis in liver transplant recipients have changed...
  2. ncbi request reprint Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients
    Atul Humar
    University of Toronto, Toronto, Ontario, Canada
    Am J Transplant 5:1065-70. 2005
    ..002). In D+/R- patients, CMV serology testing is for the most part not clinically useful for predicting subsequent disease. However, seroconversion by 6 months may be useful for identifying patients at risk of late-onset CMV disease...
  3. ncbi request reprint An assessment of interactions between hepatitis C virus and herpesvirus reactivation in liver transplant recipients using molecular surveillance
    Atul Humar
    Department of Medicine, University of Alberta, Edmonton, AB, Canada
    Liver Transpl 13:1422-7. 2007
    ..HCV-negative patients (47.6% vs. 72.7%; P=0.006). In conclusion, these results suggest that HCV infection does not appear to promote herpesvirus reactivation after liver transplantation...
  4. pmc Quinolone prophylaxis for the prevention of BK virus infection in kidney transplantation: study protocol for a randomized controlled trial
    Atul Humar
    Department of Medicine, Faculty of Medicine and Dentistry, 2J2 00 WC Mackenzie Health Sciences Centre, University of Alberta, Edmonton, AB T6G 2R7, Canada
    Trials 14:185. 2013
    ..We hypothesize that administration of a quinolone antibiotic, when given early post-transplantation, will prevent the establishment of BK viral replication in the urine and thus prevent systemic BK virus infection...
  5. pmc Differential decay kinetics of human cytomegalovirus glycoprotein B genotypes following antiviral chemotherapy
    Vincent C Emery
    Centre for Virology, Department of Infection, University College Medical School, London, United Kingdom
    J Clin Virol 54:56-60. 2012
    ..The impact of different cytomegalovirus (HCMV) glycoprotein B (gB) genotypes on pathogenesis remains controversial...
  6. doi request reprint An assessment of herpesvirus co-infections in patients with CMV disease: correlation with clinical and virologic outcomes
    A Humar
    Department of Medicine, University of Alberta, Edmonton, AB, Canada
    Am J Transplant 9:374-81. 2009
    ..Routine monitoring for viral co-infection in patients with CMV disease is not indicated...
  7. doi request reprint Nucleic acid testing (NAT) of organ donors: is the 'best' test the right test? A consensus conference report
    A Humar
    Transplant Infectious Diseases, University of Alberta
    Am J Transplant 10:889-99. 2010
    ..Further study of viral screening modalities may reduce disease transmission risk without excessive donor loss...
  8. doi request reprint The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients
    A Humar
    Department of Medicine, University of Alberta, Edmonton, AB, Canada
    Am J Transplant 10:1228-37. 2010
    ..The number needed to treat to avoid one additional patient with CMV disease up to 12 months posttransplant is approximately 5...
  9. ncbi request reprint Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study
    Atul Humar
    Transplant Infectious Diseases, University of Alberta, Edmonton, AB, Canada
    Transplantation 90:1427-31. 2010
    ..Whether the early reduction in cytomegalovirus (CMV) disease seen at 1 year with prolongation of antiviral prophylaxis (up to 200 days) persists in the long term is unknown...
  10. doi request reprint Analysis and clinical correlation of genetic variation in cytomegalovirus
    L F Lisboa
    Transplant Infectious Diseases, University of Alberta, Edmonton, Alberta, Canada
    Transpl Infect Dis 14:132-40. 2012
    ..We aimed to characterize the molecular epidemiology of gN and IE1 genotypes in organ transplant patients with CMV disease in the context of clinical and virologic endpoints...
  11. doi request reprint Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients
    D Kumar
    Transplant Infectious Diseases, University of Alberta, Edmonton, Alberta, Canada
    Am J Transplant 9:1214-22. 2009
    ..0%) patients with a detectable interferon-gamma response (cutoff 0.1 IU/mL) versus 10/25 (40.0%) patients with a negative CMI, p = 0.12. Monitoring of CMI may be useful for predicting late-onset CMV disease...
  12. doi request reprint Late cytomegalovirus transmission and impact of T-depletion in clinical islet transplantation
    B L Gala-Lopez
    Clinical Islet Transplant Program, University of Alberta, Edmonton, Alberta, Canada
    Am J Transplant 11:2708-14. 2011
    ..Therefore, CMV transmission presents rarely after IT and with low incidence compared to solid organ transplantation, but occurs late posttransplant. The use of lymphocyte depleting therapies is a primary risk factor...
  13. ncbi request reprint Human herpesvirus-6 is associated with cytomegalovirus reactivation in liver transplant recipients
    A Humar
    Department of Medicine, Division of Infectious Diseases and Multi Organ Transplantation, Toronto General Hospital University Health Network, Toronto, Ontario M5G 2C4, Canada
    J Infect Dis 181:1450-3. 2000
    ..013; odds ratio, 7.26; 95% confidence interval, 1.52-34.72). HHV-6 is associated with CMV infection and disease, thus supporting an interaction between these viruses...
  14. doi request reprint Donor-derived bacteremia in liver transplant recipients despite antibiotic prophylaxis
    K E Doucette
    Transplant Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
    Am J Transplant 13:1080-3. 2013
    ..As no transmissions occurred in recipients of nonhepatic organs from these donors, these cases also suggest that liver recipients may be at higher risk of donor transmitted bacteremia...
  15. doi request reprint Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients
    D Kumar
    Alberta Transplant Institute, University of Alberta, Edmonton, Alberta, Canada
    Am J Transplant 13:2411-7. 2013
    ..This is important for counseling patients who choose to receive this vaccine. Further studies are needed to determine an optimal HPV vaccine type and schedule for this population...
  16. doi request reprint Guidance on novel influenza A/H1N1 in solid organ transplant recipients
    D Kumar
    Transplant Infectious Diseases, University of Alberta, Edmonton, Alberta, Canada
    Am J Transplant 10:18-25. 2010
    ..As new information emerges about novel H1N1, updates will be made to the electronic version of the document posted on the websites of the AST and TTS...
  17. ncbi request reprint Comparison of quantiferon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation
    O Manuel
    Transplant Infectious Diseases, and Microbiology, University of Alberta, Edmonton, Alberta, Canada
    Am J Transplant 7:2797-801. 2007
    ..In patients awaiting liver transplantation, both the TST and QFT-G were comparable for the diagnosis of LTBI with reasonable concordance between tests. Indeterminate QFT-G result was more likely in those with more advanced liver disease...
  18. ncbi request reprint A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients
    A Humar
    Department of Medicine, Division of Infectious Diseases, Toronto General Hospital-University Health Network, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada
    Bone Marrow Transplant 28:485-90. 2001
    ..Preemptive therapy based on regular CMV antigenemia monitoring is superior to screening bronchoscopy for the prevention of CMV disease after allogeneic BMT...
  19. doi request reprint A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients
    Deepali Kumar
    Transplant Infectious Diseases, University of Alberta, Edmonton, Canada
    Clin Infect Dis 47:885-92. 2008
    ..It may be possible to enhance immunogenicity by priming the recipient with the 7-valent pneumococcal conjugate vaccine (PCV7), followed by boosting with PPV23...
  20. doi request reprint A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients
    Deepali Kumar
    Transplant Infectious Diseases, University of Alberta, Edmonton, Alberta, Canada
    Clin Infect Dis 45:1576-82. 2007
    ..Pneumococcal conjugate vaccine (PCV7) may improve immunogenicity in this population, and a donor vaccination strategy may benefit patients undergoing HSCT...
  21. doi request reprint Incidence and clinical characteristics of herpes zoster after lung transplantation
    Oriol Manuel
    Department of Transplant Infectious Diseases, University of Alberta, Edmonton, Alberta, Canada
    J Heart Lung Transplant 27:11-6. 2008
    ..Epidemiologic data in lung transplant recipients are lacking. We determined the incidence and clinical characteristics of herpes zoster, and the risk factors for developing herpes zoster, after lung transplantation...
  22. doi request reprint Lack of association between beta-herpesvirus infection and bronchiolitis obliterans syndrome in lung transplant recipients in the era of antiviral prophylaxis
    Oriol Manuel
    Transplant Infectious Diseases, University of Alberta, Edmonton, AB, Canada
    Transplantation 87:719-25. 2009
    ..We assessed the contribution of these viruses in the development of bronchiolitis obliterans syndrome (BOS) after lung transplantation...
  23. doi request reprint A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients
    Deepali Kumar
    Transplant Infectious Diseases, University of Alberta, Edmonton, Alberta, Canada
    Transplantation 89:1028-33. 2010
    ..The use of sensitive molecular methods that can simultaneously detect a large panel of respiratory viruses may help better define their effects...
  24. doi request reprint Respiratory viral infections in transplant and oncology patients
    Deepali Kumar
    Department of Medicine, Transplant Infectious Diseases, University of Alberta, 6 030 Katz Rexall Center for Health Research, Edmonton, Alberta T6G 2E1, Canada
    Infect Dis Clin North Am 24:395-412. 2010
    ..This article describes the current knowledge about respiratory viral infections as it relates to solid organ transplant, hematopoietic stem cell transplant, and oncology settings...
  25. doi request reprint Successful bilateral lung transplantation in a patient with end-stage lung disease and positive novel influenza virus (H1N1)
    Mohammed M Al Aklabi
    Division of Cardiac Surgery, Heart and Lung Transplantation, University of Alberta, Edmonton, Alberta, Alberta, Canada
    J Heart Lung Transplant 29:898-9. 2010
    ..He received three-weeks of antiviral treatment post-operatively and he had uneventful procedure with favorable outcome...
  26. pmc Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study
    Deepali Kumar
    University of Alberta, Edmonton, AB, Canada
    Lancet Infect Dis 10:521-6. 2010
    ..We aimed to establish the outcomes of pandemic influenza A H1N1 and factors leading to severe disease in a cohort of patients who had received transplants...
  27. ncbi request reprint Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation
    Atul Humar
    Department of Medicine, Multi Organ Transplantation, Toronto General Hospital, University Health Network, Department of Microbiology, University of Toronto, Toronto, Canada
    Am J Transplant 2:461-6. 2002
    ..031). In conclusion, HHV-6 and CMV infection and viral load were not associated with increased overall rates of HCV recurrence or HCV viral load after liver transplantation but may be associated with more severe forms of recurrence...
  28. doi request reprint Early post-transplant vaccination with pandemic influenza A/H1N1 vaccine in pediatric heart transplant recipients
    Luis Altamirano-Diaz
    Pediatric Heart Transplant, Stollery Children s Hospital, Transplant Infectious Diseases, University of Alberta, Edmonton, AB, Canada
    Pediatr Transplant 15:172-5. 2011
    ..Three of five developed protective titers against H1N1. A proportion of pediatric patients may respond to influenza vaccine even when immunized in the early post-transplant period...
  29. doi request reprint Pneumocystis jirovecii pneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient
    D Kumar
    Transplant Infectious Diseases, Division of Infectious Diseases, University of Alberta, Edmonton, Alberta, Canada
    Transpl Infect Dis 11:167-70. 2009
    ..After therapy with rituximab, she developed Pneumocystis jirovecii pneumonia (PJP) requiring hospitalization. We discuss the increasing literature for the use of rituximab for AMR and the need for PJP prophylaxis in this setting...
  30. doi request reprint Lung transplantation for severe antineutrophilic cytoplasmic antibody-associated vasculitis
    J Weinkauf
    Department of Medicine, University of Alberta, Edmonton, Canada
    Transplant Proc 42:2707-10. 2010
    ..Herein, we report successful lung transplantation for a patient with life-threatening pulmonary hemorrhage and respiratory failure as a consequence of this pulmonary renal syndrome...
  31. ncbi request reprint Assessment of adenovirus infection in adult lung transplant recipients using molecular surveillance
    Atul Humar
    Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    J Heart Lung Transplant 25:1441-6. 2006
    ..Little is known about adenovirus infections in adult lung transplant recipients. Because the virus can establish latency, re-activation may be relatively common after transplantation...
  32. ncbi request reprint Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease
    Atul Humar
    Department of Medicine, Division of Infectious Diseases and Multi Organ Transplantation, Toronto, Canada
    J Infect Dis 186:829-33. 2002
    ..17 days among patients without recurrence (P=.001). This was not explainable by detectable ganciclovir resistance. CMV load kinetics are useful for identifying, at a very early stage, patients who are more likely to have recurrence...
  33. ncbi request reprint Reactivation of viruses in solid organ transplant patients receiving cytomegalovirus prophylaxis
    Atul Humar
    Transplant Infectious Diseases, Division of Infectious Diseases, Toronto General Hospital, Toronto, Ontario, Canada
    Transplantation 82:S9-S14. 2006
    ..CMV prophylaxis may have modified the natural history of some of these non-CMV viral infections...
  34. doi request reprint Randomized controlled trial of high-dose intradermal versus standard-dose intramuscular influenza vaccine in organ transplant recipients
    A Baluch
    Alberta Transplant Institute, University of Alberta, Canada
    Am J Transplant 13:1026-33. 2013
    ..In this large cohort, we also show that seasonal influenza does not result in significant alloantibody production...
  35. doi request reprint Invasive pneumococcal disease in adult hematopoietic stem cell transplant recipients: a decade of prospective population-based surveillance
    D Kumar
    Division of Infectious Diseases, University of Alberta, Edmonton, Alberta, Canada
    Bone Marrow Transplant 41:743-7. 2008
    ..The antimicrobial resistance rates were high, especially for trimethoprim/sulfamethoxazole. HSCT recipients are at significantly greater risk for IPD than the general population. Preventative strategies are necessary...
  36. doi request reprint Methicillin-resistant Staphylococcus aureus infection after lung transplantation: 5-year review of clinical and molecular epidemiology
    Oriol Manuel
    Transplant Infectious Diseases, University of Alberta, Edmonton, Alberta, Canada
    J Heart Lung Transplant 28:1231-6. 2009
    ..Data on the epidemiology of MRSA infection in lung transplantation is limited...
  37. doi request reprint An assessment of donor-to-recipient transmission patterns of human cytomegalovirus by analysis of viral genomic variants
    Oriol Manuel
    Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
    J Infect Dis 199:1621-8. 2009
    ..We studied human cytomegalovirus (CMV) donor-to-recipient transmission patterns in organ transplantation by analyzing genomic variants on the basis of CMV glycoprotein B (gB) genotyping...
  38. ncbi request reprint Cytomegalovirus (CMV) glycoprotein B genotypes and response to antiviral therapy, in solid-organ-transplant recipients with CMV disease
    Atul Humar
    Department of Medicine, Division of Multi Organ Transplantation, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
    J Infect Dis 188:581-4. 2003
    ..It appears that the gB genotype, which causes CMV disease, does not significantly influence CMV-load kinetics or clinical response to therapy...
  39. ncbi request reprint Immunogenicity and safety of an intradermal boosting strategy for vaccination against influenza in lung transplant recipients
    O Manuel
    Transplant Infectious Diseases, University of Alberta, Edmonton, Alberta, Canada
    Am J Transplant 7:2567-72. 2007
    ..024). After a single standard dose of influenza vaccine, a booster dose given by intradermal injection did not significantly improve vaccine immunogenicity in lung transplant recipients...
  40. ncbi request reprint Predictors of virological response in HIV-infected patients to salvage antiretroviral therapy that includes nelfinavir
    S L Walmsley
    The Toronto Hospital Immunodeficiency Clinic, Department of Medicine, University of Toronto, Ontario, Canada
    Antivir Ther 6:47-54. 2001
    ..Response rates were lower in patients with increasing numbers of primary (P=0.045) or secondary (P=0.001) PI mutations. The addition of increasing numbers of reverse transcriptase mutations further impaired response rates (P=0.004)...
  41. ncbi request reprint Elimination of an outbreak of gram-negative bacteremia in a hemodialysis unit
    A Humar
    Department of Medicine, Ottawa General Hospital, Ontario, Canada
    Am J Infect Control 24:359-63. 1996
    ..All dialysis tubing was to be disinfected before patient connection. CONCLUSION: Outbreak was due to contamination during dialysis setup. After institution of appropriate control measures, no new cases have occurred...
  42. ncbi request reprint Travel patterns and risk behavior in solid organ transplant recipients
    Andrea K Boggild
    University of Toronto, Division of Infectious Diseases, Department of Medicine, UHN Toronto General Hospital, Toronto, ON, Canada
    J Travel Med 11:37-43. 2004
    ..We herein profile transplant recipients who travel, and characterize their pre-travel precautions, travel activities, burden of illness, and exposure history...
  43. pmc Concurrent genotyping and quantitation of cytomegalovirus gB genotypes in solid-organ-transplant recipients by use of a real-time PCR assay
    Xiaoli Pang
    Provincial Laboratory for Public Health Microbiology, University of Alberta Hospital, Edmonton, AB, Canada
    J Clin Microbiol 46:4004-10. 2008
    ..78%). With the prominent feature of concurrent CMV gB genotyping and quantitation in a single reaction, the new assay provides a rapid and cost-effective method for monitoring CMV infection in SOT recipients...
  44. doi request reprint An international survey of cytomegalovirus management practices in lung transplantation
    Dalyce M Zuk
    Lung Transplant Program, University of Alberta, Edmonton, Alberta, Canada
    Transplantation 90:672-6. 2010
    ..Cytomegalovirus (CMV) is an important infection in lung transplant recipients. Center-to-center variation in preventive and treatment strategies is unknown...
  45. doi request reprint Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease
    Oriol Manuel
    Transplant Infectious Diseases and Provincial Laboratory for Public Health Microbiology, University of Alberta, Edmonton, Alberta, Canada
    Clin Infect Dis 49:1160-6. 2009
    ..Polymorphisms in the CMV glycoprotein B (gB) gene allow discrimination of 4 distinct genotypes (gB1-gB4). We assessed the influence of gB genotypes on the clinical and virologic outcome of CMV disease...
  46. ncbi request reprint Emerging viral infections in transplant recipients
    Deepali Kumar
    Transplant Infectious Diseases, University of Toronto, Toronto, Ontario, Canada
    Curr Opin Infect Dis 18:337-41. 2005
    ..An update of emerging infections in transplant patients, using West Nile virus and severe acute respiratory syndrome as specific examples, is summarized here...
  47. ncbi request reprint Clinical impact of human herpesvirus 6 infection after liver transplantation
    Atul Humar
    Toronto General Hospital, Toronto, Ontario, Canada, M5G 2C4
    Transplantation 73:599-604. 2002
    ..The objective of this study was to determine the clinical impact of HHV-6 infection after liver transplantation including both direct and indirect effects...
  48. ncbi request reprint Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients
    Carlos Paya
    Mayo Clinic, Rochester, MN, USA
    Am J Transplant 4:611-20. 2004
    ..2%, vs 3.2% ganciclovir) the safety profile was similar for both drugs. Overall, once-daily oral valganciclovir was as clinically effective and well-tolerated as oral ganciclovir tid for CMV prevention in high-risk SOT recipients...
  49. ncbi request reprint Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients
    Richard B Freeman
    New England Medical Center of Transplant Surgery, Boston, MA 2 Mayo Clinic, Rochester, MN 02111, USA
    Transplantation 78:1765-73. 2004
    ..Cytomegalovirus (CMV) D+/R- solid-organ transplant (SOT) recipients carry increased risk of developing CMV disease; however, other risk factors in these patients have not been delineated...
  50. ncbi request reprint A report of the Lisbon Conference on the care of the kidney transplant recipient
    Mario Abbud-Filho
    Instituto de Urologia e Nefrologia and Medical School FAMERP, Sao Jose do Rio Preto SP, Brazil
    Transplantation 83:S1-22. 2007
  51. ncbi request reprint Cytomegalovirus glycoprotein B genotype does not correlate with outcomes in liver transplant patients
    Lisa Sarcinella
    Department of Microbiology, Mount Sinai Hospital, University of Toronto, 600 University Avenue, Toronto, Ont, Canada M5G 1X5
    J Clin Virol 24:99-105. 2002
    ..Previous studies have suggested there could be an association between CMV gB genotype and clinical outcome in transplant patients...
  52. ncbi request reprint Mycobacterium abscessus infections in lung transplant recipients: the international experience
    Susan M Chernenko
    Toronto Lung Transplant Program, University Health Network, University of Toronto, Toronto, Ontario, Canada
    J Heart Lung Transplant 25:1447-55. 2006
    ..The clinical significance of Mycobacterium abscessus infection in the lung transplant population is not well understood...
  53. ncbi request reprint A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients
    Atul Humar
    Department of Infectious Disease and Transplantation, University of Toronto, Ontario, Canada
    Am J Transplant 5:1462-8. 2005
    ..Valganciclovir prophylaxis had similar efficacy to either intravenous ganciclovir (D+/R- patients), or oral ganciclovir (R+ patients) in lung recipients...
  54. ncbi request reprint A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder
    Atul Humar
    Transplant Infectious Diseases, University of Toronto, and University Health Network, Toronto General Hospital, 585 University Avenue, Toronto, Ontario, Canada M5G 2N2
    Transplantation 81:856-61. 2006
    ..We performed a multi-center trial assessing two different antiviral regimens and their effect on EBV replication...
  55. ncbi request reprint Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients
    Hugh Wiltshire
    Roche Products, Welwyn Garden City, Herts, UK
    Transplantation 79:1477-83. 2005
    ....
  56. ncbi request reprint A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients
    Atul Humar
    Division of Infectious Diseases and Multi Organ Transplant Program, University of Toronto, Toronto, Canada
    J Infect Dis 192:1154-7. 2005
    ..Two patients treated with valganciclovir required a switch to iv ganciclovir, because of a lack of response. Valganciclovir is useful for the treatment of CMV infection and disease in selected organ-transplant recipients...
  57. ncbi request reprint A surveillance study of adenovirus infection in adult solid organ transplant recipients
    Atul Humar
    University of Toronto, Toronto, Ontario, Canada
    Am J Transplant 5:2555-9. 2005
    ..No serious clinical sequelae or effects on subsequent acute rejection were observed...
  58. ncbi request reprint Severe Acute Respiratory Syndrome (SARS) in a liver transplant recipient and guidelines for donor SARS screening
    Deepali Kumar
    Infectious Diseases and Multi Organ Transplant, University Health Network, University of Toronto, Ontario, Canada
    Am J Transplant 3:977-81. 2003
    ..As SARS spreads throughout the world, it may become an increasingly significant problem for transplant patients and programs...
  59. ncbi request reprint Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients
    Guy Boivin
    Research Center in Infectious Diseases, Centre Hospitalier Universitaire de Quebec and Laval University, Quebec City, Canada
    J Infect Dis 189:1615-8. 2004
    ..Valganciclovir was associated with negligible risk of resistance and thus constitutes a useful alternative to ganciclovir prophylaxis for CMV in high-risk SOT recipients...
  60. ncbi request reprint Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients
    Atul Humar
    University Health Network, Toronto General Hospital, Toronto ON, Canada
    Am J Transplant 4:644-9. 2004
    ..Similarly, single time point measures at the end of prophylaxis or month 4 had low sensitivity for disease prediction. Overall, regular CMV plasma viral load measurements were only of modest value in predicting CMV disease...
  61. ncbi request reprint Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients
    Deepali Kumar
    The Immunocompromised Host Infection Service, Division of Multi Organ Transplant and Infectious Diseases, University of Toronto, Toronto, Canada
    J Infect Dis 187:1639-45. 2003
    ..09). The response rate and mean fold increase in OPA titers were not significantly different between groups. There was a trend toward enhanced immunogenicity for PCV7 by ELISA. However, functional antibody responses were not different...
  62. ncbi request reprint Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease
    Raymund R Razonable
    Division of Infectious Diseases, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Infect Dis 192:1331-9. 2005
    ..Compared with historic data, data from the present study suggest that antiviral prophylaxis may lower the incidence, prevalence, or level of DNAemia for infection with HHV-6, HHV-8, VZV, and EBV but not for infection with HHV-7...